William Blair Sees An End To Sarepta's Regulatory Saga, Upgrades And Lifts Price Target To $88
September 19, 2016 at 11:31 AM EDT
Following Sarepta Therapeutics Inc. (NASDAQ: SRPT) receiving the U.S. Food And Drug Administration's accelerated approval for ...